01-JUL-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

50% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1564 454 29% 910 -653 802 -762
ERLYTX 76 47 62% 94 18 79 3
GI 479 104 22% 208 -270 211 -268
GU 450 251 56% 503 53 502 52
GYN 57 0 0% 0 -57 0 -57
LEUK 150 59 39% 118 -31 105 -45
LUNG 524 68 13% 136 -387 470 -54
LYMPH 172 212 123% 425 253 335 163
MELAN 55 200 364% 401 346 409 354
MMYEL 147 85 58% 170 23 264 117
MULT 0 1   2 2 8 8
OTHER 0 12   24 24 33 33
PREV 0 2   4 4 6 6
SXQOL 0 2   4 4 5 5
Total 3674 1497   2999 -671 3229 -445

01-JUL-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

50% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  0 1   2 2 1 1
BREAST 43 0 0% 0 -43 0 -43
CCD 0 56   112 112 394 394
ERLYTX 0 6   12 12 7 7
GU 0 0   0 0 2 2
LEUK 69 354 513% 709 640 546 477
LUNG 43 129 300% 258 215 277 234
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 10   20 20 21 21
PEOLC 0 39   78 78 42 42
PREV 0 85   170 170 309 309
SURV 0 0   0 0 0 0
SXQOL 888 280 32% 561 -326 639 -249
Total 1188 960   1922 735 2238 1050

01-JUL-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

50% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  0 1   2 2 1 1
BREAST 1607 454 28% 910 -696 802 -805
CCD 0 56   112 112 394 394
ERLYTX 76 53 70% 106 30 86 10
GI 479 104 22% 208 -270 211 -268
GU 450 251 56% 503 53 504 54
GYN 57 0 0% 0 -57 0 -57
LEUK 219 413 189% 828 609 651 432
LUNG 567 197 35% 395 -171 747 180
LYMPH 225 212 94% 425 200 335 110
MELAN 55 200 364% 401 346 409 354
MMYEL 239 85 36% 170 -68 264 25
MULT 0 1   2 2 8 8
OTHER 0 22   44 44 54 54
PEOLC 0 39   78 78 42 42
PREV 0 87   174 174 315 315
SURV 0 0   0 0 0 0
SXQOL 888 282 32% 565 -322 644 -244
Total 4862 2457   4923 66 5467 605

01-JUL-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

50% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1018 285 28% 571 -446 490 -528
ERLYTX 76 27 36% 54 -21 47 -29
GI 421 76 18% 152 -268 163 -258
GU 375 218 58% 437 62 434 59
GYN 57 0 0% 0 -57 0 -57
LEUK 122 37 30% 74 -47 66 -56
LUNG 441 45 10% 90 -350 287 -154
LYMPH 129 137 106% 274 145 221 92
MELAN 55 122 222% 244 189 242 187
MMYEL 85 56 66% 112 27 167 82
MULT 0 1   2 2 6 6
OTHER 0 12   24 24 33 33
PREV 0 2   4 4 6 6
SXQOL 0 2   4 4 5 5
Total 2779 1020   2042 -732 2167 -612

01-JUL-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

50% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  0 1   2 2 1 1
BREAST 16 0 0% 0 -16 0 -16
CCD 0 52   104 104 326 326
ERLYTX 0 6   12 12 7 7
GU 0 0   0 0 2 2
LEUK 69 156 226% 312 243 240 171
LUNG 30 73 243% 146 116 152 122
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 10   20 20 21 21
PEOLC 0 24   48 48 27 27
PREV 0 84   168 168 308 308
SURV 0 0   0 0 0 0
SXQOL 750 186 25% 373 -376 434 -316
Total 1010 592   1185 176 1518 508

01-JUL-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

50% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  0 1   2 2 1 1
BREAST 1034 285 28% 571 -462 490 -544
CCD 0 52   104 104 326 326
ERLYTX 76 33 43% 66 -9 54 -22
GI 421 76 18% 152 -268 163 -258
GU 375 218 58% 437 62 436 61
GYN 57 0 0% 0 -57 0 -57
LEUK 191 193 101% 387 196 306 115
LUNG 471 118 25% 236 -234 439 -32
LYMPH 182 137 75% 274 92 221 39
MELAN 55 122 222% 244 189 242 187
MMYEL 177 56 32% 112 -64 167 -10
MULT 0 1   2 2 6 6
OTHER 0 22   44 44 54 54
PEOLC 0 24   48 48 27 27
PREV 0 86   172 172 314 314
SURV 0 0   0 0 0 0
SXQOL 750 188 25% 377 -372 439 -311
Total 3789 1612   3228 -555 3685 -104

01-JUL-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

50% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 65 448 689% 898 833 790 725
CCD 0 56   112 112 394 394
ERLYTX 0 1   2 2 1 1
GI 81 34 42% 68 -12 52 -29
GU 215 177 82% 354 139 362 147
LEUK 0 26   52 52 47 47
LUNG 53 43 81% 86 33 115 62
LYMPH 7 47 671% 94 87 97 90
MELAN 0 0   0 0 0 0
MMYEL 0 82   164 164 254 254
OTHER 0 4   8 8 15 15
PEOLC 0 39   78 78 42 42
PREV 0 87   174 174 183 183
SURV 0 0   0 0 0 0
SXQOL 880 282 32% 565 -314 644 -236
Total 1301 1326   2655 1356 2996 1695

01-JUL-2025 6:11

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm. Phase Study Stat
Center		 Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure
    NRGGY028 NRG     1      
BREAST II EA1211 Breast, HER2+, NeoAdj Therapy ECOG-ACRIN 10MAY2023:00:00:00   9   0.5  
    NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG 13APR2017:00:00:00   7     Dec-2022 Temp Close
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1     May-2022 Temp Close
  III A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib ALLIANCE 06JAN2021:00:00:00   55   0.7  
    A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab ALLIANCE 03MAY2023:00:00:00   33   3.0  
    A012301 Breast, Early Stg, Tamoxifen ALLIANCE 05FEB2025:00:00:00   6   1.2  
    MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG 30MAY2018:00:00:00   56   2.3  
    NRGBR007 Breast, Stg I, De-Escalation of Breast RT NRG 07JUN2021:00:00:00   23   1.2  
    NRGBR008 Breast, LowRisk HER2+, Radiotherapy NRG 13MAR2023:00:00:00   1   0.2  
    NRGBR009 Breast, EarlyStg, Adjuvant Chemo NRG 31AUG2023:00:00:00   15   1.2  
    S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva SWOG 30OCT2023:00:00:00 20 193 960 16.8 Apr-2029
    S2212 Breast, TNBC, Neoadj Chemo + Pembro SWOG 21JUL2023:00:00:00 23 721 2400 48.3 May-2028
CCD III A191901 Brst, Text/Motivational Intervention ET Adher ALLIANCE 10DEC2020:00:00:00   42   0.2  
    S1703 Met Breast, STM-monitoring v Usual Care SWOG 16JUL2018:00:00:00 83 412 498 6.0 Sep-2026
  OTHER A231602C Blood Cancer, Assess Financial Difficulty ALLIANCE 15MAR2019:00:00:00   4     Feb-2021 Temp Close
    ACCL16N1 Guideline Consistent Treatment AYA ALL COG 18DEC2017:00:00:00   54     Aug-2022 Temp Close
    EAQ221CD Breast, Metastatic, Imp. Adherence ECOG-ACRIN 31OCT2023:00:00:00   3   0.5  
    EAQ222CD CostCOM, Cancer Patients, OOP Cost Com ECOG-ACRIN 29FEB2024:00:00:00   21   2.7  
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 28AUG2015:00:00:00   8   0.0  
    EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib SWOG 06MAR2023:00:00:00 27 22 33 2.3 Nov-2025
    EAY191A3 ComboMATCH-RAS-Mutant, All Stg, Palbo+Benim ALLIANCE 15NOV2023:00:00:00   2   0.0  
    EAY191A6 ComboMATCH: MAPK Tumors, Adv Stg, FOLFOX+Bin ALLIANCE 11AUG2023:00:00:00   2   0.2  
  II-III S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo SWOG 02DEC2021:00:00:00 42 105 189 5.2 Nov-2026
  III AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult COG 08MAY2017:00:00:00   3   0.2  
  OTHER EAY191 ComboMATCH ECOG-ACRIN 06MAR2023:00:00:00   17   1.0  
GI II A022104 Rectal, Loc Adv, Triplet vs Doublet Chemo ALLIANCE 09NOV2022:00:00:00   107   4.2  
    CCTGNE1 Midgut NET, Unresect, 177 Lut vs Ever CCTG 05JUN2023:00:00:00   4   0.0  
    EA2192 Panc, APOLLO ECOG-ACRIN 29APR2021:00:00:00   6   0.3  
    S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect SWOG 16DEC2019:00:00:00 66 42 54 0.3 Jun-2028
    S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo SWOG 04DEC2020:00:00:00 54 70 88 1.7 May-2026
    S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs SWOG 14OCT2021:11:13:50 44 72 154 2.7 Jan-2028
  II-III EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab ECOG-ACRIN 17JAN2019:00:00:00   6   0.0  
    NRGGI008 Colon, Stg III, Adj Chemo NRG 10MAR2022:00:00:00   34   1.2  
    S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo SWOG 06MAY2024:00:00:00 13 41 224 4.7 Oct-2028
  III A021806 Pancreas, Perioperative vs Adjuvant Chemo ALLIANCE 01JUL2020:00:00:00   33   0.3  
    A022101 Colorectal, Metastatic, Ablative Tx ALLIANCE 10JAN2023:00:00:00   1   0.2  
    A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo ALLIANCE 11JAN2023:00:00:00   30   0.7  
    CCTGCO32 Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad CCTG 29FEB2024:00:00:00   7   0.7  
    EA2222 Colorectal, Stg II-III, Hep Art Infusion ECOG-ACRIN 19OCT2023:00:00:00   4   0.3  
    NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG 07NOV2017:00:00:00 91 15   0.0  
    NRGGI006 Esophagus, Stg I-IVA, PBT vs IMRT NRG 06MAR2019:00:00:00   1   0.0  
GU II A031701 Bladder, ddGC for MIBC with DDR Tumor Alt ALLIANCE 01AUG2018:00:00:00   24   0.2  
    A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) ALLIANCE 12APR2019:00:00:00   27   0.0  
    A031801 GU, mRCC, Cabozantinib ± Radium-223 ALLIANCE 13DEC2019:00:00:00   15   0.0  
    A031803 Blad, NMIBC, Gemcitabine + MK-3475 ALLIANCE 06JAN2020:00:00:00   47   0.0  
    NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx NRG 08DEC2021:00:00:00   18   1.2  
    NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy NRG 30JUN2022:00:00:00   7   0.2  
    S2200 pRCC, Adv, Cabo ± Atezo SWOG 19SEP2022:00:00:00 33 34 200 0.8 > 15 Yrs
    S2210 Pros, High Risk, BRCA, Neoadj Carbo SWOG 14AUG2023:00:00:00 22 5 44 0.3 Mar-2035
  II-III A032103 Urothelial, All Stg, MRD-Based Adj Tx ALLIANCE 09JAN2024:00:00:00   21   3.0  
    EA8192 Blad, High Grade UTUC, Durv + Chemo ECOG-ACRIN 06MAY2021:00:00:00   4   0.0  
  III EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT ECOG-ACRIN 08SEP2017:00:00:00   19   1.0  
    EA8191 Pros, Local vs Systemic Thrpy ECOG-ACRIN 08OCT2020:00:00:00   65   0.8  
    EA8212 Blad, NMIBC, BRIDGE ECOG-ACRIN 01DEC2022:00:00:00   248   11.0  
    NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide NRG 05MAR2020:00:00:00   14   0.0  
    NRGGU009 Pros, PREDICT-RT NRG 15DEC2020:00:00:00   87   1.2  
    NRGGU010 Pros, Parallel De-Intens & Intens Trials NRG 03NOV2021:00:00:00   63   0.3  
    NRGGU013 Prostate, High-Risk, Five Fraction Radiation NRG 13NOV2023:00:00:00   9   0.7  
    S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum SWOG 17SEP2018:00:00:00 81 933 1273 10.3 Mar-2028
    S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only SWOG 16NOV2020:00:00:00 55 129 332 2.8 Jun-2031
    S1937 Blad, Mets, Eribulin + Gem vs SOC SWOG 16FEB2021:00:00:00 52 91 184 4.5 Mar-2027
    S2312 Pros, MCRPC, Cab +/- Carb SWOG 03SEP2024:00:00:00 9 23 500 3.5 Nov-2036
LEUK I-II S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 SWOG 17AUG2020:00:00:00 58 20 67 0.3 Mar-2037
  II A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat ALLIANCE 16NOV2018:00:00:00   5   0.0  
    EA9213 T-ALL, dara-hyal for chemo refractory MRD ECOG-ACRIN 16JUN2022:00:00:00   3   0.0  
    MM1OA-S03 AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena SWOG 01APR2025:00:00:00 3 2 102    
    MM1OAEA02 MyeloMATCH: AML, New Dx, Ven+HMA ECOG-ACRIN 06JUN2024:00:00:00   4   0.3  
    MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental SWOG 16MAY2024:00:00:00 13 23 335 3.0 Feb-2034
    MM1YACTG01 AML, New/Young/Intermediate, Ven+Chemo CCTG 18JUL2024:00:00:00   3   0.2  
  III A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo ALLIANCE 01JUN2017:00:00:00   44   0.0  
    EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab ECOG-ACRIN 14OCT2020:00:00:00   45   0.7  
    S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O SWOG 14DEC2020:00:00:00 54 152 247 4.3 Apr-2027
  OTHER MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials SWOG 16MAY2024:00:00:00 13 551   59.0  
LUNG II EA5162 NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 ECOG-ACRIN 05APR2018:00:00:00   4   0.5  
    S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu SWOG 03APR2023:00:00:00 26 21 66 0.7 Feb-2031
    S1900J MET Amplification: Amivantamab-SC SWOG 27SEP2024:10:59:58 9 2 88 0.2 > 15 Yrs
    S1900K MET Exon 14: Tepotinib +/- Ramucirumab SWOG 18DEC2023:00:00:00 18 10 56 1.2 Oct-2028
    S1933 NSCLC, Stg II-III, RT + Atezo SWOG 15JUN2020:10:15:53 60 45 47 0.7 Sep-2025
  II-III A082002 Lung, Adv, Systemic Tx +/- SBRT ALLIANCE 21DEC2021:00:00:00   4   0.0  
    S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab SWOG 28APR2025:10:50:48 2 3 378    
  III A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO ALLIANCE 03JUN2020:00:00:00   92   0.8  
    EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 ECOG-ACRIN 22OCT2020:00:00:00   24   0.5  
    EA5221 Lung, Advanced NSCLC, ChemoImmuno/Immuno ECOG-ACRIN 15FEB2024:00:00:00   2   0.2  
    NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo NRG 10MAY2023:00:00:00   3   0.2  
    S1827 SCLC, MRI Surveillance +/- PCI SWOG 10JAN2020:00:00:00 65 285 668 5.7 Feb-2031
    S2402 NSCLC, All Stg, Periop Vs Adj Tx ALLIANCE 11DEC2024:00:00:00   4   0.7  
    S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance SWOG 14MAR2025:00:00:00 3 2 306 0.6 > 15 Yrs
  OTHER LUNGMAP NSCLC, Adv, Master SWOG 28JAN2019:00:00:00 77 3666   20.5  
LYMPH II A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P ALLIANCE 30JUL2021:00:00:00   17   0.8  
    S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation SWOG 23FEB2023:11:55:36 28 143 396 7.5 Apr-2028
    S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa SWOG 30JUN2023:11:49:39 24 27 227 0.0 > 15 Yrs
  II-III S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP SWOG 19MAR2021:00:00:00   136 422   Apr-2025 Temp Close
  III A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub ALLIANCE 08SEP2023:00:00:00   19   0.8  
    AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy COG 28APR2023:00:00:00   62   5.0  
    S2308 FL, LTB, Mosunetuzumab vs Rituximab SWOG 01AUG2024:00:00:00 11 126 600 18.5 Aug-2027
MELAN II A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo ALLIANCE 01JUN2022:00:00:00   1   0.0  
    EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy ECOG-ACRIN 27AUG2020:00:00:00   10   0.2  
  II-III EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 10SEP2015:00:00:00   73   0.7  
  III S2015 MELAN, Stg I-II, 1cm v 2cm excision margins MASC 08APR2022:00:00:00   1086   32.5  
MMYEL II EAA173 MYEL, SMM, Rd +/- Daratumumab ECOG-ACRIN 30APR2019:00:00:00   37   0.0  
    S2005 WM, Prev. Untreated, I/R +/- Venetoclax SWOG 24JUN2021:00:00:00 48 15 92 0.5 Apr-2038
  III EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) ECOG-ACRIN 27OCT2020:00:00:00   41   0.7  
    S1803 MM, Maintenance, Len vs Len/Dara SWOG 27JUN2019:00:00:00 72 1337 1100 7.3 Nov-2022
    S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D SWOG 30MAY2023:00:00:00 25 85 510 4.5 May-2033
    S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT SWOG 01DEC2023:00:00:00 19 14 338 1.2 > 15 Yrs
MMYL II A062102 MMYL, All Stg, Iberdomide Tx ALLIANCE 04APR2024:00:00:00   0   0.0  
MULT II S2101 Melan or HNSCC, Adv, Cabo + Nivo SWOG 14OCT2022:10:48:23 32 55 220 0.2 > 15 Yrs
OTHER I NRGGY022 Mult Site/Stg, Carboplat Clearance Predict NRG 18NOV2019:00:00:00   3   0.0  
  II A071701 BRAIN, Met, Geno-guided trial ALLIANCE 15AUG2019:00:00:00   2   0.0  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   22   0.0  
    EA3191 HN, High Risk HNSCC, Adj +/- Pembro ECOG-ACRIN 08JAN2021:00:00:00   13   0.2  
    NRGGY032 Endo, ErlyStg Pole/p53, Adj Tx NRG 16APR2024:00:00:00   1   0.2  
    NRGHN010 HER2+ SGC, T-DM1 vs TH NRG 30SEP2022:00:00:00   4   0.0  
  II-III NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE NRG 12AUG2022:00:00:00   2   0.2  
    NRGHN006 HN, Erly Stg, Biopsy vs Dissection NRG 08JUL2020:00:00:00   3   0.0  
    NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN NRG 27OCT2021:00:00:00   18   0.2  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   7   0.0  
  III AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo COG 30JUL2018:00:00:00   5     Temp Close
    CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx CCTG 29SEP2022:00:00:00   1   0.0  
    CE7 Brain, 5+ Metastases, Radiosurg/Radiotherapy CCTG 25MAY2018:00:00:00   1   0.0  
    EA7222 Sarcoma, Poorly Diff, Dox+Pembro vs Dox ECOG-ACRIN 13JUN2024:00:00:00   3   0.5  
    NRGBN003 Mening, Grd II, Observation vs Irradiation NRG 14JUN2017:00:00:00   3   0.0  
    NRGBN011 Brain, Lomustine + Temo vs Temo NRG 29NOV2021:00:00:00   11   0.3  
    NRGBN012 Brain, Pre- vs Post-Op Stereotactic Radiosurg NRG 31AUG2022:00:00:00   4   0.0  
    NRGBN013 Brain, Intact Metas, SRS vs FSRS NRG 28AUG2024:00:00:00   3   0.3  
    NRGGY036 Ovary, All Stg, Olaparib +/- Bevac NRG 16JAN2025:00:00:00   2   0.4  
  OTHER A151804 irAEs, National Biorepository to Adv Studies ALLIANCE 31JAN2020:00:00:00   44   1.5  
PEOLC III S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 93 347 491 5.7 Aug-2027
    S2408 Panc Fistula Prevention, Lanreotide SWOG 14FEB2025:00:00:00 4 5 274 1.1 > 15 Yrs
PREV II EA2185 Panc, Impact of Panc Cyst Surveillance ECOG-ACRIN 16JAN2020:00:00:00   19   0.0  
  III NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs NRG 06OCT2021:00:00:00   77   6.8  
  OTHER A212102 Blind Ref Set for Multicancer Early Detection ALLIANCE 01AUG2022:00:00:00   217   7.2  
    NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO NRG 23JUN2020:00:00:00   12   0.2  
SXQOL III A211901 Cancer survivors who smoke, txt cessation ALLIANCE 01DEC2021:00:00:00   14   0.2  
    A222004 Mult, Olanza vs Megestrol for Anorexia ALLIANCE 15OCT2021:00:00:00   7   0.0  
    ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis COG 14AUG2023:00:00:00   5   0.5  
    NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction NRG 19SEP2022:00:00:00   15   0.3  
    NRGCC011 Breast, Survivors, Cog Training NRG 02FEB2024:00:00:00   35   1.5  
    S2205 ICE COMPRESS: Reduction of CIPN from Taxanes SWOG 16MAR2023:00:00:00 27 390 777 19.3 Mar-2027
  OTHER S2013 I-CHECKIT: ICI toxicity risk prediction study SWOG 16AUG2021:00:00:00 46 2231 3609 22.2 Sep-2030
  PILOT EAQ202 Improving AYA PROs in EA Trials ECOG-ACRIN 28OCT2021:00:00:00   43   0.0  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

01-JUL-2025 6:11

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase Comm. Int
grp		 Stat
Center		 Study NCIPROTO CA
Cntrl
Study		 Temp
Close
OTHER CCD     EAQ221CD Breast, Metastatic, Imp. Adherence   Y  
        EAQ222CD CostCOM, Cancer Patients, OOP Cost Com   Y  
    Y COG ACCL16N1 Guideline Consistent Treatment AYA ALL ACCL16N1CD Y Y
    Y ALLIANCE A231602C Blood Cancer, Assess Financial Difficulty A231602CD Y Y
  ERLYTX Y ECOG-ACRIN EAY191 ComboMATCH EAY191 N  
  LEUK Y SWOG MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials MYELOMATCH N  
  LUNG Y SWOG LUNGMAP NSCLC, Adv, Master LUNGMAP N  
  OTHER Y ALLIANCE A151804 irAEs, National Biorepository to Adv Studies A151804 N  
  PREV Y ALLIANCE A212102 Blind Ref Set for Multicancer Early Detection A212102 Y  
    Y NRG NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO NRG-CC008 Y  
  SXQOL Y SWOG S2013 I-CHECKIT: ICI toxicity risk prediction study S2013 Y  
I OTHER Y NRG NRGGY022 Mult Site/Stg, Carboplat Clearance Predict NRG-GY022 N  
I-II LEUK Y SWOG S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 S1905 N  
II BREAST Y NRG NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG-BR005 N Y
    Y ECOG-ACRIN EA1211 Breast, HER2+, NeoAdj Therapy EA1211 N  
  ERLYTX Y SWOG EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib EAY191-S3 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
    Y ALLIANCE EAY191A6 ComboMATCH: MAPK Tumors, Adv Stg, FOLFOX+Bin EAY191-A6 N  
    Y ALLIANCE EAY191A3 ComboMATCH-RAS-Mutant, All Stg, Palbo+Benim EAY191-A3 N  
  GI     EA2192 Panc, APOLLO   N  
    Y SWOG S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo S2001 N  
    Y SWOG S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect S1922 N  
    Y SWOG S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs S2104 N  
    Y ALLIANCE A022104 Rectal, Loc Adv, Triplet vs Doublet Chemo A022104 N  
    Y CCTG CCTGNE1 Midgut NET, Unresect, 177 Lut vs Ever CCTG-NE1 Y  
  GU Y SWOG S2200 pRCC, Adv, Cabo ± Atezo S2200 N  
    Y SWOG S2210 Pros, High Risk, BRCA, Neoadj Carbo S2210 N  
    Y ALLIANCE A031701 Bladder, ddGC for MIBC with DDR Tumor Alt A031701 N  
    Y ALLIANCE A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) A031702 N  
    Y ALLIANCE A031803 Blad, NMIBC, Gemcitabine + MK-3475 A031803 N  
    Y NRG NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx NRG-GU011 Y  
    Y NRG NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy NRG-GU012 N  
    Y ALLIANCE A031801 GU, mRCC, Cabozantinib ± Radium-223 A031801 Y  
  LEUK     EA9213 T-ALL, dara-hyal for chemo refractory MRD   N  
    Y SWOG MM1OA-S03 AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena MM1OA-S03 N  
    Y SWOG MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental MM1YA-S01 N  
    Y ECOG-ACRIN MM1OAEA02 MyeloMATCH: AML, New Dx, Ven+HMA MM1OA-EA02 N  
    Y ALLIANCE A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat A041703 N  
    Y CCTG MM1YACTG01 AML, New/Young/Intermediate, Ven+Chemo MM1YA-CTG01 N  
  LUNG Y SWOG S1933 NSCLC, Stg II-III, RT + Atezo S1933 N  
    Y SWOG S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu S1900G N  
    Y SWOG S1900K MET Exon 14: Tepotinib +/- Ramucirumab S1900K N  
    Y SWOG S1900J MET Amplification: Amivantamab-SC S1900J N  
    Y ECOG-ACRIN EA5162 NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 EA5162 N  
  LYMPH Y SWOG S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa S2207 Y  
    Y SWOG S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation S2114 N  
    Y ALLIANCE A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P A051902 N  
  MELAN     A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo   N  
    Y ECOG-ACRIN EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy EA6192 N  
  MMYEL Y SWOG S2005 WM, Prev. Untreated, I/R +/- Venetoclax S2005 N  
    Y ECOG-ACRIN EAA173 MYEL, SMM, Rd +/- Daratumumab EAA173 Y  
  MMYL     A062102 MMYL, All Stg, Iberdomide Tx   N  
  MULT Y SWOG S2101 Melan or HNSCC, Adv, Cabo + Nivo S2101 N  
  OTHER Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
    Y NRG NRGHN010 HER2+ SGC, T-DM1 vs TH NRG-HN010 N  
    Y ALLIANCE A071701 BRAIN, Met, Geno-guided trial A071701 N  
    Y NRG NRGGY032 Endo, ErlyStg Pole/p53, Adj Tx NRG-GY032 N  
    Y ECOG-ACRIN EA3191 HN, High Risk HNSCC, Adj +/- Pembro EA3191 N  
  PREV Y ECOG-ACRIN EA2185 Panc, Impact of Panc Cyst Surveillance EA2185 Y  
PILOT SXQOL Y ECOG-ACRIN EAQ202 Improving AYA PROs in EA Trials EAQ202 Y  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N Y
  ERLYTX Y SWOG S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo S2012 N  
  GI Y SWOG S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo S2303 Y  
    Y ECOG-ACRIN EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab EA2174 N  
    Y NRG NRGGI008 Colon, Stg III, Adj Chemo NRG-GI008 N  
  GU     A032103 Urothelial, All Stg, MRD-Based Adj Tx   Y  
    Y ECOG-ACRIN EA8192 Blad, High Grade UTUC, Durv + Chemo EA8192 N  
  LUNG Y SWOG S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab S1800E N  
    Y ALLIANCE A082002 Lung, Adv, Systemic Tx +/- SBRT A082002 Y  
  LYMPH Y SWOG S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP S1918 Y Y
  MELAN Y ECOG-ACRIN EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN006 HN, Erly Stg, Biopsy vs Dissection NRG-HN006 Y  
    Y NRG NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN NRG-HN009 Y  
    Y NRG NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE NRG-GY026 Y  
III BREAST Y SWOG S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva S2206 Y  
    Y SWOG S2212 Breast, TNBC, Neoadj Chemo + Pembro S2212 Y  
    Y CCTG MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG MA.39 Y  
    Y ALLIANCE A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib A011801 Y  
    Y ALLIANCE A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab A012103 Y  
    Y NRG NRGBR009 Breast, EarlyStg, Adjuvant Chemo NRG-BR009 Y  
    Y NRG NRGBR008 Breast, LowRisk HER2+, Radiotherapy NRG-BR008 Y  
    Y ALLIANCE A012301 Breast, Early Stg, Tamoxifen A012301 Y  
    Y NRG NRGBR007 Breast, Stg I, De-Escalation of Breast RT NRG-BR007 Y  
  CCD Y SWOG S1703 Met Breast, STM-monitoring v Usual Care S1703 Y  
    Y ALLIANCE A191901 Brst, Text/Motivational Intervention ET Adher A191901 Y  
  ERLYTX Y COG AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult AGCT1531 Y  
  GI     A022101 Colorectal, Metastatic, Ablative Tx   N  
    Y NRG NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG-GI004 N  
    Y NRG NRGGI006 Esophagus, Stg I-IVA, PBT vs IMRT NRG-GI006 Y  
    Y CCTG CCTGCO32 Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad CCTG-CO32 Y  
    Y ECOG-ACRIN EA2222 Colorectal, Stg II-III, Hep Art Infusion EA2222 N  
    Y ALLIANCE A021806 Pancreas, Perioperative vs Adjuvant Chemo A021806 Y  
    Y ALLIANCE A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo A022102 N  
  GU N   S2312 Pros, MCRPC, Cab +/- Carb   N  
    Y SWOG S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum S1802 Y  
    Y SWOG S1937 Blad, Mets, Eribulin + Gem vs SOC S1937 N  
    Y SWOG S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only S1931 N  
    Y ECOG-ACRIN EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT EA8134 Y  
    Y NRG NRGGU013 Prostate, High-Risk, Five Fraction Radiation NRG-GU013 Y  
    Y NRG NRGGU010 Pros, Parallel De-Intens & Intens Trials NRG-GU010 Y  
    Y ECOG-ACRIN EA8191 Pros, Local vs Systemic Thrpy EA8191 Y  
    Y ECOG-ACRIN EA8212 Blad, NMIBC, BRIDGE EA8212 Y  
    Y NRG NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide NRG-GU008 Y  
    Y NRG NRGGU009 Pros, PREDICT-RT NRG-GU009 Y  
  LEUK Y SWOG S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O S1925 Y  
    Y ALLIANCE A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo A041501 N  
    Y ECOG-ACRIN EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab EA9181 N  
  LUNG     EA5221 Lung, Advanced NSCLC, ChemoImmuno/Immuno   Y  
    Y SWOG S1827 SCLC, MRI Surveillance +/- PCI S1827 Y  
    Y SWOG S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance S2414 Y  
    Y NRG NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo NRG-LU008 Y  
    Y ALLIANCE A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO A081801 Y  
    Y ECOG-ACRIN EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 EA5182 N  
    Y ALLIANCE S2402 NSCLC, All Stg, Periop Vs Adj Tx CTIU2317-A082304-S2402 N  
  LYMPH Y SWOG S2308 FL, LTB, Mosunetuzumab vs Rituximab S2308 N  
    Y ALLIANCE A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub A052101 Y  
    Y COG AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy AHOD2131 Y  
  MELAN Y MASC S2015 MELAN, Stg I-II, 1cm v 2cm excision margins S2015 N  
  MMYEL Y SWOG S1803 MM, Maintenance, Len vs Len/Dara S1803 Y  
    Y SWOG S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D S2209 Y  
    Y SWOG S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT S2213 Y  
    Y ECOG-ACRIN EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) EAA181 Y  
  OTHER     CE7 Brain, 5+ Metastases, Radiosurg/Radiotherapy   Y  
    Y NRG NRGGY036 Ovary, All Stg, Olaparib +/- Bevac NRG-GY036 N  
    Y NRG NRGBN003 Mening, Grd II, Observation vs Irradiation NRG-BN003 Y  
    Y COG AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo AGCT1532 Y Y
    Y CCTG CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx CCTG-HN11 Y  
    Y NRG NRGBN011 Brain, Lomustine + Temo vs Temo NRG-BN011 Y  
    Y NRG NRGBN013 Brain, Intact Metas, SRS vs FSRS NRG-BN013 N  
    Y NRG NRGBN012 Brain, Pre- vs Post-Op Stereotactic Radiosurg NRG-BN012 Y  
    Y ECOG-ACRIN EA7222 Sarcoma, Poorly Diff, Dox+Pembro vs Dox EA7222 N  
  PEOLC Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y SWOG S2408 Panc Fistula Prevention, Lanreotide S2408 Y  
  PREV Y NRG NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs NRG-CC005 Y  
  SXQOL     NRGCC011 Breast, Survivors, Cog Training   Y  
    Y SWOG S2205 ICE COMPRESS: Reduction of CIPN from Taxanes S2205 Y  
    Y ALLIANCE A211901 Cancer survivors who smoke, txt cessation A211901 Y  
    Y COG ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis ACCL1931 Y  
    Y ALLIANCE A222004 Mult, Olanza vs Megestrol for Anorexia A222004 Y  
    Y NRG NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction NRG-CC010 Y  
    Y NRG NRGGY028 NRG-GY028    

01-JUL-2025 6:11

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

Protocol
Number		 Study Accrual
Goal		 Open
Stat/Date		 Months
Open		 Accrual
as of
01Jan02		 Current Accrual Proj.
Annual
Accr.
Rate		 EXPCLOSE Proj.
Study
Duration
(Years)
S1501 S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol (PEOLC) 491 Y-09/15/17 93 347 347 68 Aug-2027 9.9
S1703 S1703 Met Breast, STM-monitoring v Usual Care (CCD) 498 Y-07/16/18 83 412 412 72 Sep-2026 8.1
S1800E S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab (LUNG) 378 Y-04/28/25 2 3 3      
S1802 S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum (GU) 1273 Y-09/17/18 81 933 933 124 Mar-2028 9.5
S1803 S1803 MM, Maintenance, Len vs Len/Dara (MMYEL) 1100 Y-06/27/19 72 1337 1337 88 Nov-2022 3.3
S1827 S1827 SCLC, MRI Surveillance +/- PCI (LUNG) 668 Y-01/10/20 65 285 285 68 Feb-2031 11.1
S1918 S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP (LYMPH) 422 T-03/19/21 51 136 136 24 May-2037 > 15 Yrs
S1925 S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O (LEUK) 247 Y-12/14/20 54 152 152 52 Apr-2027 6.3
S1931 S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only (GU) 332 Y-11/16/20 55 129 129 34 Jun-2031 10.5
S1937 S1937 Blad, Mets, Eribulin + Gem vs SOC (GU) 184 Y-02/16/21 52 91 91 54 Mar-2027 6.0
S2012 S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo (ERLYTX) 189 Y-12/02/21 42 105 105 62 Nov-2026 4.9
S2205 S2205 ICE COMPRESS: Reduction of CIPN from Taxanes (SXQOL) 777 Y-03/16/23 27 390 390 232 Mar-2027 4.0
S2206 S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva (BREAST) 960 Y-10/30/23 20 193 193 202 Apr-2029 5.4
S2209 S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D (MMYEL) 510 Y-05/30/23 25 85 85 54 May-2033 9.9
S2212 S2212 Breast, TNBC, Neoadj Chemo + Pembro (BREAST) 2400 Y-07/21/23 23 721 721 580 May-2028 4.8
S2213 S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT (MMYEL) 338 Y-12/01/23 19 14 14 14 > 15 Yrs > 15 Yrs
S2303 S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo (GI) 224 Y-05/06/24 13 41 41 56 Oct-2028 4.4
S2308 S2308 FL, LTB, Mosunetuzumab vs Rituximab (LYMPH) 600 Y-08/01/24 11 126 126 222 Aug-2027 3.0
S2312 Pros, MCRPC, Cab +/- Carb (GU) 500 Y-09/03/24 9 23 23 42 Nov-2036 12.2
S2408 S2408 Panc Fistula Prevention, Lanreotide (PEOLC) 274 Y-02/14/25 4 5 5 13.074868 > 15 Yrs > 15 Yrs
S2414 S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance (LUNG) 306 Y-03/14/25 3 2 2 6.6871806 > 15 Yrs > 15 Yrs
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.